What is the potential share price of IBRX in the next month based on new treatment approvals in Saudi Arabia and possible new approvals in U.S.A.

The recent accelerated approvals for ImmunityBio's (IBRX) ANKTIVA® in Saudi Arabia for metastatic non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC) are significant developments. The NSCLC approval is particularly notable as it marks the first global approval for this indication and the first for subcutaneous administration.1 The NMIBC approval expands upon existing approvals in the U.S. and U.K..2 These regulatory successes can act as catalysts, potentially enhancing market penetration and future revenue streams. ImmunityBio has already reported strong preliminary net product revenue for ANKTIVA, reaching approximately $113.0 million for the full year 2025, a substantial 700% increase year-over-year.3

While these international approvals are positive, the impact of "possible new approvals in U.S.A." on near-term share price remains speculative. The U.S. regulatory process is stringent and can be lengthy, and the outcome of ongoing clinical trials for new indications is inherently uncertain. For example, the Saudi approval for NSCLC is a global first, implying it is not yet approved in the U.S. for this specific use.1

To assess potential share price movements, it is important to consider broader market sentiment and fundamental data available on Fintel:

• Analyst Price Targets: The average one-year price target for IBRX is $11.63, with forecasts ranging from $5.05 to $31.50. This range reflects varying professional opinions on the stock's long-term valuation.4
• Institutional Ownership: Fintel data indicates significant institutional interest, with 373 institutional owners holding IBRX shares, totaling over 92 million shares. Major holders include Vanguard Group Inc and BlackRock, Inc..5
• Short Interest: IBRX has a substantial short interest of 76,978,537 shares, with a Short Interest % Float of 58.54% and a Days to Cover ratio of 13.19. High short interest can contribute to increased volatility and the potential for a short squeeze if positive news continues to emerge.6

Investors should closely monitor SEC filings, particularly 8-K reports for material events, and 10-K/10-Q filings for detailed financial performance and risk factors. Fintel's platform provides tools to track these filings, institutional ownership changes, and short interest data, offering a comprehensive view of the stock's dynamics.

Based on today's price movement, is IBRX potentially entering a gamma squeeze?

A gamma squeeze occurs when a rapid increase in a stock's price forces market makers, who are typically short gamma, to buy the underlying shares to hedge their long call option positions. This hedging activity can create a positive feedback loop, pushing the stock price even higher. This phenomenon is often amplified in stocks with high short interest, as short sellers may also be forced to cover their positions, contributing to a short squeeze.

For ImmunityBio (IBRX), several factors suggest it could be susceptible to such a dynamic, though confirming an active gamma squeeze requires real-time options flow and open interest data.

• High Short Interest: IBRX has a substantial short interest, with 76.98 million shares sold short, representing 58.54% of its float and a Days to Cover ratio of 13.19. This high short interest means that any significant upward price movement could trigger short covering, adding fuel to a potential squeeze.1
• Options Sentiment (Put/Call OI Ratio): The Put/Call Open Interest Ratio for IBRX stands at 0.29. A ratio below 1 typically indicates a bullish sentiment among options traders, as there are more open call options than put options. This suggests that a significant number of traders are betting on the stock's price increasing.2
• Implied Volatility: IBRX's implied volatility is 88.93%, which is relatively high. High implied volatility indicates that the market anticipates significant price movements, which is a characteristic often seen in stocks prone to squeezes.2

While these indicators point to a potential for volatility and upward movement, to definitively assess if IBRX is entering a gamma squeeze based on "today's price movement," one would need to examine:

• Unusual Call Options Volume: A sudden surge in call option purchases, particularly out-of-the-money calls, indicates increased bullish speculation.
• Open Interest at Key Strikes: A concentration of open interest at specific strike prices, especially just above the current stock price, can create "gamma walls" that market makers must hedge as the price approaches those levels.
• Real-time Options Flow: Monitoring large block trades in call options can reveal institutional positioning that might precede a significant move.

Investors can utilize Fintel's "Gamma Squeeze" and "Options Flow" tools to track these real-time metrics and identify potential squeeze conditions.

Analyze IBRX's daily options volume and open interest across various strike prices for the most recent trading day.